Skip to content
easybpt
Browse topics

Pharmacology

Cholinesterase inhibitors, memantine and anticholinergic burden

How donepezil, rivastigmine and galantamine differ, why cholinergic effects cause bradycardia, syncope and incontinence, memantine's uncompetitive NMDA block and renal clearance, and how anticholinergic burden scales and the Drug Burden Index are calculated.

Tier 2Medical sciences concept

Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made

3 questions9 flashcards

At a glance

  • Alzheimer disease destroys cholinergic neurons in the nucleus basalis of Meynert. Cholinesterase inhibitors (ChEIs) raise synaptic acetylcholine and give a modest symptomatic benefit (about 1 to 2 MMSE points, or 2 to 3 ADAS-Cog points, over 6 months). They don't change the course.
  • Memantine dampens excess glutamate signalling and is used in moderately severe disease.
  • Anticholinergic drugs push the other way. They are common, cumulative and linked to delirium, falls, cognitive decline and dementia.

Loading the rest of the note…

Finished reading?

Test yourself on it:3 questions9 flashcards

Sources

Last updated
14 November 2026
What changed
  • 14 November 2026 Turnstile bot check on sign-in and signed-out feedback

Send feedback

Type of feedback

The page you're on and your device type are attached automatically.